Benepali Surge And Imraldi Gains Drive Biogen Biosimilars Past US$500m
With sales climbing by more than two-fifths last year, Biogen expects its biosimilar sales to continue to grow by double digits in 2019, driven by the launch of the Imraldi adalimumab biosimilar in mid-October last year.
You may also be interested in...
Biogen Claims Lead Among Adalimumab Biosimilars In Europe
With quarterly sales up to $36m, Biogen says its Imraldi rival to Humira is the market-leading adalimumab biosimilar in Europe.
Imraldi sets pace on German price cuts
Biogen’s Imraldi (adalimumab) biosimilar has entered the German market with a list price just over 40% lower than the cost of the reference brand, AbbVie’s Humira, according to the association of statutory health insurance doctors for the North Rhine region, the KVNO. And while Amgen’s Amgevita and Sandoz/Hexal’s Hyrimoz currently offer more modest list-price discounts to Humira, the KVNO says both suppliers of adalimumab biosimilars have announced price cuts that will come into effect from 15 November.
Biogen says sales will slow but lauds supply
Biogen has warned that sales growth for its biosimilars is likely to slow in the second half of 2018, with pricing pressure projected to outweigh volume growth. Nevertheless, the US-based firm believes that the strength of its supply chain will help it maintain a “competitive advantage”, in an increasingly burgeoning market, as Biogen also eyes introducing one of the first Humira (adalimumab) biosimilars in the fourth quarter.